Free Trial

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Has Average Target Price of $12.10 According to Analysts

CytomX Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts give CytomX a “Moderate Buy” consensus: nine of 12 brokerages rate the stock a buy, one a strong buy, one a hold and one a sell. Their average 12-month price target is $12.10.
  • The company reported a quarterly loss of $0.09 per share, missing the $0.07 loss consensus; revenue was $1.69 million versus analysts’ $10.38 million expectation.
  • CTMX opened at $2.04, near its 52-week low of $1.90, while institutional investors own 67.77% of its shares.
  • Interested in CytomX Therapeutics? Here are five stocks we like better.

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have earned an average rating of "Moderate Buy" from the twelve brokerages that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, nine have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $12.10.

A number of equities analysts have commented on CTMX shares. Wedbush boosted their price objective on shares of CytomX Therapeutics from $11.00 to $12.00 and gave the stock an "outperform" rating in a report on Friday, November 6th. Zacks Research downgraded CytomX Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 19th. Guggenheim lowered their target price on CytomX Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Monday, August 10th. JPMorgan Chase & Co. lifted their target price on CytomX Therapeutics from $11.00 to $12.00 and gave the stock an "overweight" rating in a research report on Thursday. Finally, Wall Street Zen upgraded CytomX Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, November 7th.

Get Our Latest Report on CytomX Therapeutics

Institutional Investors Weigh In On CytomX Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in shares of CytomX Therapeutics in the 2nd quarter worth about $65,849,000. Bank of America Corp DE acquired a new stake in shares of CytomX Therapeutics in the 2nd quarter valued at about $56,560,000. Perceptive Advisors LLC raised its stake in shares of CytomX Therapeutics by 4.3% in the 1st quarter. Perceptive Advisors LLC now owns 10,098,824 shares of the biotechnology company's stock valued at $47,464,000 after purchasing an additional 418,639 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of CytomX Therapeutics by 44.3% in the 2nd quarter. Wellington Management Group LLP now owns 5,168,961 shares of the biotechnology company's stock valued at $19,384,000 after purchasing an additional 1,585,976 shares in the last quarter. Finally, Elmind Capital LP lifted its position in shares of CytomX Therapeutics by 550.0% during the first quarter. Elmind Capital LP now owns 4,550,000 shares of the biotechnology company's stock worth $21,385,000 after purchasing an additional 3,850,000 shares during the last quarter. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

CytomX Therapeutics Price Performance

CTMX opened at $2.04 on Monday. The firm's 50 day moving average is $2.56 and its 200-day moving average is $3.72. CytomX Therapeutics has a 52-week low of $1.90 and a 52-week high of $8.21. The firm has a market capitalization of $444.74 million, a P/E ratio of -4.08 and a beta of 2.23.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last announced its earnings results on Thursday, November 5th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The firm had revenue of $1.69 million during the quarter, compared to analysts' expectations of $10.38 million. CytomX Therapeutics had a negative net margin of 608.98% and a negative return on equity of 33.97%. Equities analysts expect that CytomX Therapeutics will post -0.39 earnings per share for the current fiscal year.

About CytomX Therapeutics

(Get Free Report)

CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer treatments. Founded in 2008 and headquartered in South San Francisco, California, the company researches therapies designed to target tumors while limiting activity in healthy tissues. Its Probody platform uses molecular masks intended to keep therapeutic antibodies inactive until they encounter enzymes associated with the tumor environment. CytomX applies this approach to investigational medicines, including antibody-drug conjugates and immune-cell-engaging therapies.

Featured Stories

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CytomX Therapeutics Right Now?

Before you consider CytomX Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytomX Therapeutics wasn't on the list.

While CytomX Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines